HUMA / Humacyte, Inc. (HUMA) CEO Laura Niklason on Q4 2021 Results - Earnings Call Transcript

Humacyte develops regenerative human tissue for various medical uses, with upcoming BLAs and interest from the US military. Their core technology, Hum more_horizontal

Humacyte Inc. (NASDAQ:HUMA ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Dr. Laura Niklason - President & CEO Dal more_horizontal

On May 25, 2023, Heather Prichard, the Chief Operating Officer (COO) of Humacyte Inc ( HUMA , Financial), sold 23,402 shares of the company. This move more_horizontal

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per more_horizontal

Humacyte (HUMA) surges as it completes patient enrollment in a late-stage clinical study on the human acellular vessel product for vascular access in more_horizontal

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 12.50% and 100%, respectively, for the quarter ended December 2022. Do the numbers h more_horizontal

DURHAM, N.C., March 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally more_horizontal

Humacyte, Inc. (NASDAQ:HUMA ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Lauren Marek - Investor Relations Laura Ni more_horizontal